Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to -$9.7 million.

  • Fulcrum Therapeutics' Net Income towards Common Stockholders rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year increase of 24.63%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
  • As of FY2024, Fulcrum Therapeutics' Net Income towards Common Stockholders stood at -$9.7 million, which was up 90.01% from -$97.3 million recorded in FY2023.
  • Fulcrum Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$9.7 million for FY2024, and its period low was -$109.9 million during FY2022.
  • In the last 3 years, Fulcrum Therapeutics' Net Income towards Common Stockholders had a median value of -$97.3 million in 2023 and averaged -$72.3 million.
  • In the last 5 years, Fulcrum Therapeutics' Net Income towards Common Stockholders tumbled by 35.90% in 2022 and then surged by 90.01% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Net Income towards Common Stockholders stood at -$70.8 million in 2020, then declined by 14.16% to -$80.8 million in 2021, then tumbled by 35.90% to -$109.9 million in 2022, then grew by 11.41% to -$97.3 million in 2023, then surged by 90.01% to -$9.7 million in 2024.